AR096092A1 - ANTI-IGF-1R ANTIBODIES WITH ABOLITION OF THE UNION TO THE FcRn AND ITS USE IN THE TREATMENT OF VASCULAR EYE DISEASES - Google Patents

ANTI-IGF-1R ANTIBODIES WITH ABOLITION OF THE UNION TO THE FcRn AND ITS USE IN THE TREATMENT OF VASCULAR EYE DISEASES

Info

Publication number
AR096092A1
AR096092A1 ARP140101717A ARP140101717A AR096092A1 AR 096092 A1 AR096092 A1 AR 096092A1 AR P140101717 A ARP140101717 A AR P140101717A AR P140101717 A ARP140101717 A AR P140101717A AR 096092 A1 AR096092 A1 AR 096092A1
Authority
AR
Argentina
Prior art keywords
abolition
fcrn
igf
antibodies
treatment
Prior art date
Application number
ARP140101717A
Other languages
Spanish (es)
Inventor
Schlothauer Tilman
Schaefer Wolfgang
Hartmann Guido
Rueth Matthias
Thomas Regula Joerg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR096092A1 publication Critical patent/AR096092A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpos anti-IGF-1R (receptor del factor de crecimiento de tipo insulínico humano 1) con abolición de la unión al FcRn (receptor de Fc neonatal humana) y métodos de utilización de los mismos para el tratamiento de enfermedades oculares vasculares. Método para inhibir, formulación farmacológica, administración.Anti-IGF-1R antibodies (human insulin-like growth factor 1 receptor) with abolition of binding to FcRn (human neonatal Fc receptor) and methods of using them for the treatment of vascular eye diseases. Method to inhibit, pharmacological formulation, administration.

ARP140101717A 2013-04-29 2014-04-25 ANTI-IGF-1R ANTIBODIES WITH ABOLITION OF THE UNION TO THE FcRn AND ITS USE IN THE TREATMENT OF VASCULAR EYE DISEASES AR096092A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13165741 2013-04-29

Publications (1)

Publication Number Publication Date
AR096092A1 true AR096092A1 (en) 2015-12-02

Family

ID=48190315

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101717A AR096092A1 (en) 2013-04-29 2014-04-25 ANTI-IGF-1R ANTIBODIES WITH ABOLITION OF THE UNION TO THE FcRn AND ITS USE IN THE TREATMENT OF VASCULAR EYE DISEASES

Country Status (3)

Country Link
AR (1) AR096092A1 (en)
MA (1) MA38561B1 (en)
MY (1) MY181915A (en)

Also Published As

Publication number Publication date
MY181915A (en) 2021-01-14
MA38561A1 (en) 2017-09-29
MA38561B1 (en) 2018-09-28

Similar Documents

Publication Publication Date Title
UY35258A (en) ANTI-PDGFR-beta ANTIBODIES AND USES OF THE SAME
PE20181300A1 (en) CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF CANCER
AR102712A1 (en) INSULIN RECEPTOR PARTIAL AGONISTS
CO7160093A2 (en) Anti-egfr antibodies and uses thereof
UY36779A (en) NEW DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
ECSP19046893A (en) NEW COMPOUNDS AS TRIGONAL PEPTIDIC AGONISTS OF GLP1 / GLUCAGON / GIP RECEPTORS
DOP2015000246A (en) DERIVATIVES OF REPLACED OXOPIRIDINE AND USES OF THE SAME IN THE TREATMENT OF CARDIOVASCULAR DISORDERS
CR20150585A (en) ANTI-IGF-1R ANTIBODIES WITH ABOLITION OF THE UNION TO THE FCRN AND ITS USE IN THE TREATMENT OF VASCULAR EYE DISEASES
UY36179A (en) DERIVATIVES OF EXENDINA-4 AS SELECTIVE AGONISTS OF THE GLUCAGON RECEIVER
CL2015002501A1 (en) Compounds and uses of these for hemoglobin modulation
CL2016000436A1 (en) Method for the treatment of fibrotic disease
DOP2014000255A (en) BICYCLICALLY REPLACED URACILES AND USE OF THE SAME
AR095555A1 (en) THERAPEUTIC USE OF ANTIBODIES DIRECTED TO THE HEPATOCITE GROWTH FACTOR (HGF)
CL2015002835A1 (en) New pyridine derivatives
CL2015002202A1 (en) Benzamides substituted with activity towards ep4 receptors.
GT201800018A (en) ANTI-CD154 ANTIBODY WITH IMPROVED BINDING, FUNCTIONALITY AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY
GT201500168A (en) STABILIZED POLIPEPTIDES OF THE INSULIN TYPE GROWTH FACTOR
GT201400153A (en) DERIVATIVES OF SPIROINDOLINE AS ANTAGONISTS OF THE RECEIVER OF GONADOTROPINE HORMONE LIBERATOR
CO2020006855A2 (en) Compositions and methods for cd2 + cell depletion
MX2020004516A (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells.
MX2020004411A (en) Anti-cd40 antibodies for use in treatment of sjögren's syndrome.
BR112015028737A2 (en) methods for hormone production and / or purification
MX2016002502A (en) Bendamustine pharmaceutical compositions.
AR096092A1 (en) ANTI-IGF-1R ANTIBODIES WITH ABOLITION OF THE UNION TO THE FcRn AND ITS USE IN THE TREATMENT OF VASCULAR EYE DISEASES
NI201500172A (en) PHARMACEUTICAL COMPOSITIONS